- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 619207, 6 pages
Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases
1Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
2Cardiovascular Division and Lillehei Heart Institute, University of Minnesota, Minneapolis, MN 55455, USA
Received 13 April 2013; Accepted 29 May 2013
Academic Editor: Keji Chen
Copyright © 2013 Xiaoyu Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- C.-A. Chen, L. J. Druhan, S. Varadharaj, Y.-R. Chen, and J. L. Zweier, “Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme,” Journal of Biological Chemistry, vol. 283, no. 40, pp. 27038–27047, 2008.
- Y. Chen, J. H. Traverse, R. Du, M. Hou, and R. J. Bache, “Nitric oxide modulates myocardial oxygen consumption in the failing heart,” Circulation, vol. 106, no. 2, pp. 273–279, 2002.
- Y. Chen, J. H. Traverse, M. Hou, Y. Li, R. Du, and R. J. Bache, “Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure,” The American Journal of Physiology, vol. 284, no. 5, pp. H1513–H1520, 2003.
- J. H. Traverse, P. Melchert, G. L. Pierpont, B. Jones, M. Crampton, and R. J. Bache, “Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise,” Circulation Research, vol. 84, no. 4, pp. 401–408, 1999.
- P. L. Huang, Z. Huang, H. Mashimo et al., “Hypertension in mice lacking the gene for endothelial nitric oxide synthase,” Nature, vol. 377, no. 6546, pp. 239–242, 1995.
- W. Li, S. Mital, C. Ojaimi, A. Csiszar, G. Kaley, and T. H. Hintze, “Premature death and age-related cardiac dysfunction in male eNOS-knockout mice,” Journal of Molecular and Cellular Cardiology, vol. 37, no. 3, pp. 671–680, 2004.
- R. H. Böger, L. M. Sullivan, E. Schwedhelm et al., “Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community,” Circulation, vol. 119, no. 12, pp. 1592–1600, 2009.
- S. J. Nicholls, Z. Wang, R. Koeth et al., “Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction,” Circulation, vol. 116, no. 20, pp. 2315–2324, 2007.
- E. Takimoto, H. C. Champion, M. Li et al., “Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1221–1231, 2005.
- L. A. Barouch, R. W. Harrison, M. W. Skaf et al., “Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms,” Nature, vol. 416, no. 6878, pp. 337–340, 2002.
- L. A. Barouch, T. P. Cappola, R. W. Harrison et al., “Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice,” Journal of Molecular and Cellular Cardiology, vol. 35, no. 6, pp. 637–644, 2003.
- S. P. Jones, J. J. M. Greer, R. van Haperen, D. J. Duncker, R. de Crom, and D. J. Lefer, “Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4891–4896, 2003.
- M. Scherrer-Crosbie, R. Ullrich, K. D. Bloch et al., “Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice,” Circulation, vol. 104, no. 11, pp. 1286–1291, 2001.
- F. Ichinose, K. D. Bloch, J. C. Wu et al., “Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency,” The American Journal of Physiology, vol. 286, no. 3, pp. H1070–H1075, 2004.
- H. Ruetten, S. Dimmeler, D. Gehring, C. Ihling, and A. M. Zeiher, “Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload,” Cardiovascular Research, vol. 66, no. 3, pp. 444–453, 2005.
- E. S. Buys, M. J. Raher, S. L. Blake et al., “Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload,” The American Journal of Physiology, vol. 293, no. 1, pp. H620–H627, 2007.
- S. Janssens, P. Pokreisz, L. Schoonjans et al., “Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction,” Circulation Research, vol. 94, no. 9, pp. 1256–1262, 2004.
- I. N. Mungrue, R. Gros, X. You et al., “Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death,” Journal of Clinical Investigation, vol. 109, no. 6, pp. 735–743, 2002.
- G. A. Haywood, P. S. Tsao, H. E. von der Leyen et al., “Expression of inducible nitric oxide synthase in human heart failure,” Circulation, vol. 93, no. 6, pp. 1087–1094, 1996.
- F. M. Habib, D. R. Springall, G. J. Davies, C. M. Oakley, M. H. Yacoub, and J. M. Polak, “Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy,” The Lancet, vol. 347, no. 9009, pp. 151–155, 1996.
- P. Zhang, X. Xu, X. Hu, E. D. Van Deel, G. Zhu, and Y. Chen, “Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure,” Circulation Research, vol. 100, no. 7, pp. 1089–1098, 2007.
- A. J. Cardounel, H. Cui, A. Samouilov et al., “Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial no production and vascular function,” Journal of Biological Chemistry, vol. 282, no. 2, pp. 879–887, 2007.
- Q. Feng, L. Xiangru, A. J. Fortin et al., “Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure,” Cardiovascular Research, vol. 37, no. 3, pp. 667–675, 1998.
- J. T. Kielstein, S. M. Bode-Böger, G. Klein, S. Graf, H. Haller, and D. Fliser, “Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure,” European Journal of Clinical Investigation, vol. 33, no. 5, pp. 370–375, 2003.
- A. Surdacki, M. Nowicki, J. Sandmann et al., “Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension,” Journal of Cardiovascular Pharmacology, vol. 33, no. 4, pp. 652–658, 1999.
- K. Sydow, C. E. Mondon, and J. P. Cooke, “Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA,” Vascular Medicine, vol. 10, no. 1, pp. S35–S43, 2005.
- R. H. Böger, S. M. Bode-Böger, P. S. Tsao, P. S. Lin, J. R. Chan, and J. P. Cooke, “An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes,” Journal of the American College of Cardiology, vol. 36, no. 7, pp. 2287–2295, 2000.
- H.-B. Xiao, Z.-C. Yang, S.-J. Jia et al., “Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice,” Life Sciences, vol. 81, no. 1, pp. 1–7, 2007.
- Y. Chen, Y. Li, P. Zhang et al., “Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts,” The American Journal of Physiology, vol. 289, no. 5, pp. H2212–H2219, 2005.
- F. Cosentino, S. Patton, L. V. d'Uscio et al., “Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats,” Journal of Clinical Investigation, vol. 101, no. 7, pp. 1530–1537, 1998.
- U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension,” Journal of Clinical Investigation, vol. 111, no. 8, pp. 1201–1209, 2003.
- Y. Xia, V. L. Dawson, T. M. Dawson, S. H. Snyder, and J. L. Zweier, “Nitric oxide synthase generates Superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 13, pp. 6770–6774, 1996.
- M.-H. Zou, C. Shi, and R. A. Cohen, “Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite,” Journal of Clinical Investigation, vol. 109, no. 6, pp. 817–826, 2002.
- K. J. Baek, B. A. Thiel, S. Lucas, and D. J. Stuehr, “Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme,” Journal of Biological Chemistry, vol. 268, no. 28, pp. 21120–21129, 1993.
- B. R. Crane, A. S. Arvai, D. K. Ghosh et al., “Structure of nitric oxide synthase oxygenase dimer with pterin and substrate,” Science, vol. 279, no. 5359, pp. 2121–2126, 1998.
- Y. Xia and J. L. Zweier, “Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 13, pp. 6954–6958, 1997.
- N. M. Olken, Y. Osawa, and M. A. Marletta, “Characterization of the inactivation of nitric oxide synthase by N(G)-methyl-L-arginine: evidence for heme loss,” Biochemistry, vol. 33, no. 49, pp. 14784–14791, 1994.
- A. J. Cardounel, Y. Xia, and J. L. Zweier, “Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin,” Journal of Biological Chemistry, vol. 280, no. 9, pp. 7540–7549, 2005.
- F. Scalera, J. Borlak, B. Beckmann et al., “Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1816–1822, 2004.
- J. Toth, A. Racz, P. M. Kaminski, M. S. Wolin, Z. Bagi, and A. Koller, “Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone,” Hypertension, vol. 49, no. 3, pp. 563–568, 2007.
- S. M. Wells and A. Holian, “Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells,” The American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 5, pp. 520–528, 2007.
- T. Ogawa, M. Kimoto, and K. Sasaoka, “Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats,” Biochemical and Biophysical Research Communications, vol. 148, no. 2, pp. 671–677, 1987.
- J. M. Leiper, J. Santa Maria, A. Chubb et al., “Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases,” Biochemical Journal, vol. 343, no. 1, pp. 209–214, 1999.
- C. T. L. Tran, M. F. Fox, P. Vallance, and J. M. Leiper, “Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins,” Genomics, vol. 68, no. 1, pp. 101–105, 2000.
- F. I. Arrigoni, P. Vallance, S. G. Haworth, and J. M. Leiper, “Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia,” Circulation, vol. 107, no. 8, pp. 1195–1201, 2003.
- X. Hu, D. Atzler, X. Xu et al., “Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 7, pp. 1540–1546, 2011.
- H. Dayoub, V. Achan, S. Adimoolam et al., “Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence,” Circulation, vol. 108, no. 24, pp. 3042–3047, 2003.
- X. Hu, X. Xu, G. Zhu et al., “Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine,” Circulation, vol. 120, no. 22, pp. 2222–2229, 2009.
- J. Leiper, M. Nandi, B. Torondel et al., “Disruption of methylarginine metabolism impairs vascular homeostasis,” Nature Medicine, vol. 13, no. 2, pp. 198–203, 2007.
- P. Zhang, X. Hu, X. Xu, Y. Chen, and R. J. Bache, “Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 4, pp. 890–897, 2011.
- T. Ikegami and Y. Matsuzaki, “Ursodeoxycholic acid: mechanism of action and novel clinical applications,” Hepatology Research, vol. 38, no. 2, pp. 123–131, 2008.
- P. B. Hylemon, H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent, “Bile acids as regulatory molecules,” Journal of Lipid Research, vol. 50, no. 8, pp. 1509–1520, 2009.
- M. Trauner, T. Claudel, P. Fickert, T. Moustafa, and M. Wagner, “Bile acids as regulators of hepatic lipid and glucose metabolism,” Digestive Diseases, vol. 28, no. 1, pp. 220–224, 2010.
- D. J. Parks, S. G. Blanchard, R. K. Bledsoe et al., “Bile acids: natural ligands for an orphan nuclear receptor,” Science, vol. 284, no. 5418, pp. 1365–1368, 1999.
- J. Sinisalo, H. Vanhanen, P. Pajunen, H. Vapaatalo, and M. S. Nieminen, “Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease,” British Journal of Clinical Pharmacology, vol. 47, no. 6, pp. 661–665, 1999.
- P. R. Maloney, D. J. Parks, C. D. Haffner et al., “Identification of a chemical tool for the orphan nuclear receptor FXR,” Journal of Medicinal Chemistry, vol. 43, no. 16, pp. 2971–2974, 2000.
- K. Ma, P. K. Saha, L. Chan, and D. D. Moore, “Farnesoid X receptor is essential for normal glucose homeostasis,” Journal of Clinical Investigation, vol. 116, no. 4, pp. 1102–1109, 2006.
- C. J. Sinal, M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, and F. J. Gonzalez, “Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis,” Cell, vol. 102, no. 6, pp. 731–744, 2000.
- J. A. Talwalkar and K. D. Lindor, “Primary biliary cirrhosis,” The Lancet, vol. 362, no. 9377, pp. 53–61, 2003.
- L. Schild, F. Dombrowski, U. Lendeckel, C. Schulz, A. Gardemann, and G. Keilhoff, “Impairment of endothelial nitric oxide synthase causes abnormal fat and glycogen deposition in liver,” Biochimica et Biophysica Acta, vol. 1782, no. 3, pp. 180–187, 2008.
- L. Schild, I. Jaroscakova, U. Lendeckel, G. Wolf, and G. Keilhoff, “Neuronal nitric oxide synthase controls enzyme activity pattern of mitochondria and lipid metabolism,” FASEB Journal, vol. 20, no. 1, pp. 145–147, 2006.
- U. Özcan, E. Yilmaz, L. Özcan et al., “Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes,” Science, vol. 313, no. 5790, pp. 1137–1140, 2006.
- S. von Haehling, J. C. Schefold, E. A. Jankowska et al., “Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial,” Journal of the American College of Cardiology, vol. 59, no. 6, pp. 585–592, 2012.
- T. Hu, M. Chouinard, A. L. Cox et al., “Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation,” Journal of Biological Chemistry, vol. 281, no. 52, pp. 39831–39838, 2006.
- J. Li, A. Wilson, X. Gao et al., “Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 1, pp. 234–243, 2009.
- A. Mencarelli, S. Cipriani, B. Renga et al., “FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, pp. 94–101, 2013.
- L. Zhang, T. Li, D. Yu, B. M. Forman, and W. Huang, “FXR protects lung from lipopolysaccharide-induced acute injury,” Molecular Endocrinology, vol. 26, no. 1, pp. 27–36, 2012.